tradingkey.logo

Heron Therapeutics Inc <HRTX.OQ> expected to post a loss of 1 cent a share - Earnings Preview

ReutersMay 2, 2025 1:46 PM
  • Heron Therapeutics Inc HRTX.OQ HRTX.O is expected to show a rise in quarterly revenue when it reports results on May 6 for the period ending March 31 2025

  • The Cary North Carolina-based company is expected to report a 7.9% increase in revenue to $37.417 million from $34.67 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Heron Therapeutics Inc is for a loss of 1 cent per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00​, above​ its last closing price of $2.35. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.03

-0.03

0.02

Beat

175

Sep. 30 2024

-0.03

-0.03

-0.03

Met

10

Jun. 30 2024

-0.04

-0.04

-0.06

Missed

-50​

Mar. 31 2024

-0.08

-0.09

-0.02

Beat

77.8

​​Dec. 31 2023

-0.16

-0.16

-0.07

Beat

57.2

Sep. 30 2023

-0.29

-0.29

-0.17

Beat

41.9​

Jun. 30 2023

-0.23

-0.23

-0.35

Missed

-50

Mar. 31 2023

-0.21

-0.20

-0.27

Missed

-33

This summary was machine generated May 2 at 13:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI